摘要:
A method of monotherapy for a subject suffering from abnormal cell growth expressing the epidermal growth factor receptor (EGFR) which comprises orally administering to the subject a therapeutically effective amount of a crystalline polymorph of the hydrochloride salt of N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine so as to treat the subject.
摘要:
The present invention relates to a stable crystalline form of N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine hydrochloride designated the B polymorph, its production in essentially pure form, and its use. The invention also relates to the pharmaceutical compositions containing the stable polymorph B form of N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine as hydrochloride, as well other forms of the compound, and to methods of treating hyperproliferative disorders, such as cancer, by administering the compound.
摘要:
User Equipment (UE) in receipt of a session start signal indicating a session frequency to use for a session along with other user equipment uses the session frequency until a session stop message is received and then changes to a frequency selected to avoid subsequent use of a same frequency used by the other user equipment. For instance, when the UE receives a Multimedia Broadcast Multicast Service (MBMS) session start signal and it contains a preferred frequency, the Radio Resource Control (RRC) layer of the UE could store the frequency of the serving cell for later reference. The UE then converges to the preferred frequency for the duration of the session. When the UE receives a session stop, RRC layer retrieves the previously stored information about the pre-session frequency and requests the physical layer (L1) to select a cell on the frequency where it was previously camped on.
摘要:
A process is described for preparing a compound of Formula (1.3.0): comprising: establishing a reaction mixture consisting of in an aprotic solvent; in the presence of NaOH or KOH; optionally in the presence of a phase transfer catalyst, especially a quaternary ammonium salt or a phosphonium salt; followed by heating said reaction mixture under a nitrogen atmosphere.
摘要:
The invention relates to a non-hygroscopic polymorph of the following compound ##STR1## and to pharmaceutical compositions containing the above compound, methods of treating bacterial infections by administering the above compound, and to methods of preparing the above compound and related compounds.
摘要:
The present invention relates to a stable crystalline form of N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine hydrochloride designated the B polymorph, its production in essentially pure form, and its use. The invention also relates to the pharmaceutical compositions containing the stable polymorph B form of N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine as hydrochloride, as well other forms of the compound, and to methods of treating hyperproliferative disorders, such as cancer, by administering the compound.
摘要:
This invention relates to methods of preparing sodium-hydrogen exchanger type 1 (NHE-1) inhibitors of formula I′ intermediates of the NHE-1 inhibitors and a new almost colorless form of the NHE-1 inhibitor N-(5-cyclopropyl-1-quinolin-5-yl-1H-pyrazole-4-carbonyl)-guanidine.
摘要:
Two crystalline polymorphic forms of (2-Benzhydryl-1-azo-bicyclo(2.2.2]Octyl-3-yl)-(5-iso-propyl-2-methoxybenzyl)amine dihydrochloride dihydrate are Form I and Form II. The pharmaceutical composition containing at least are of these polymorphs has advantageous stability for formulation to treat emesis in patients receiving chemotherapy. The administration of this pharmaceutical composition is conventional oral by preferably tablet or capsule or intravenous. A method of making Forms I and II is also disclosed.
摘要:
Apparatus, computer program products and methods allow inclusion and segmentation of multiple SDUs within a PDU, and generate information (such as header information) necessary to identify, e.g., the position of the segmented SDUs within the PDU. Prior knowledge of the typically used (i.e., predetermined) SDU size is used to perform segmentation operations, hi one exemplary variant, apparatus, methods and computer program products determine if a particular one of a set of input data units (SDUs) is to be segmented in order to fit a portion of the set, including a segment of the particular input data unit, into an output data unit (PDU); segment the input data unit in response to determining the particular input data unit is to be segmented; add the portion of the set to a data portion of the output data unit, and add into the output data unit an indication of a position of the segment in the data portion. In another variant, apparatus, computer program products and methods receive first data units, each of the first data units including a plurality of data portions having a plurality of second data units, each of at least two of the first data units including an indication of a position of a segment of a second data unit in associated ones of the data portions; combine using at least the indications the segments to create a complete second data unit; and output the complete second data unit.